Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 9/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924298 | 1.00 | ALB (0.54) | ALBCA9FOLH1SIRT2SIRT1 | |
| SCHEMBL19933029 | 0.94 | ALB (0.49) | ALBCA9FOLH1CA12CA1 | |
| Trifluoroacetic Acid SCHEMBL30646991 | 0.94 | ALB (0.48) | ALBCA9FOLH1SIRT2SIRT1 | |
| SCHEMBL22021340 | 0.90 | ALB (0.45) | ALBFOLH1GRIK1 | |
| SCHEMBL22021341 | 0.89 | ALB (0.46) | ALBFOLH1 | |
| SCHEMBL22021344 | 0.88 | PLAAT3 (0.48) | ALBCA9SIRT2SIRT1CA12 | |
| SCHEMBL19929584 | 0.88 | ALB (0.41) | ALBCA9SIRT2SIRT1CA12 | |
| SCHEMBL26548495 | 0.88 | ALB (0.41) | ALBCA9FOLH1SIRT2SIRT1 | |
| SCHEMBL19929586 | 0.88 | ALB (0.41) | ALBCA9SIRT2SIRT1CA12 | |
| SCHEMBL26548503 | 0.88 | ALB (0.41) | ALBCA9SIRT2SIRT1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939617-B2 | Functionally modified polypeptides and radiobiosynthesis | IKARIA INC. (US) | 2024-03-26 | — | — | US | claimed |
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2023-10-19 | — | — | US | claimed |
| WO-2018045376-A2 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IKARIA INC. (US) | 2018-03-08 | — | — | WO | claimed |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2018-03-08 | — | — | US | claimed |
| US-11939617-B2 | Functionally modified polypeptides and radiobiosynthesis | IKARIA INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11214820-B2 | Functionally modified polypeptides and radiobiosynthesis | IKARIA INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939617-B2 | Functionally modified polypeptides and radiobiosynthesis | IL1RN, IL2RA, IL1A | ALB 31/4885CA9 3993/4885FOLH1 253/4885 |
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | ALB 31/4885CA9 3993/4885FOLH1 253/4885 |
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | ALB, TTR, ABCG2 | ALB 1/4885CA9 702/4885FOLH1 19/4885 |
| US-11214820-B2 | Functionally modified polypeptides and radiobiosynthesis | IL1RN, IL2RA, IL1A | ALB 31/4885CA9 3993/4885FOLH1 253/4885 |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | ALB 31/4885CA9 3993/4885FOLH1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.